Comparative Pharmacology
Head-to-head clinical analysis: GONITRO versus NITROGLYCERIN IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONITRO versus NITROGLYCERIN IN DEXTROSE 5.
GONITRO vs NITROGLYCERIN IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels and causing venous and arterial dilation.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.
None Documented
None Documented
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Terminal elimination half-life: 1–4 minutes; clinical context: rapid clearance due to extensive metabolism by glutathione-S-transferase and glutathionylation.
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Renal: ~33% as intact drug; hepatic metabolism accounts for >90% of clearance; biliary/fecal: negligible.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator